Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
BACKGROUND Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. OBJECTIVES To evaluate the efficacy and safety of rituximab for MS treatment. DATA COLLECTION Studies were selected if they were clinical trials, irrespective of the dosage or combination therapies. MAIN RESULTS Four studies w...
متن کاملDouble-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
BACKGROUND Therapeutic options are limited in secondary progressive multiple sclerosis (SPMS). Open-label studies suggested efficacy of monthly IV cyclophosphamide (CPM) without induction for delaying progression but no randomized trial was conducted so far. OBJECTIVE To compare CPM to methylprednisolone (MP) in SPMS. METHODS Randomized, double-blind clinical trial on two parallel groups. P...
متن کاملDemyelination versus remyelination in progressive multiple sclerosis.
The causes of incomplete remyelination in progressive multiple sclerosis are unknown, as are the pathological correlates of the different clinical characteristics of patients with primary and secondary progressive disease. We analysed brains and spinal cords from 51 patients with progressive multiple sclerosis by planimetry. Thirteen patients with primary progressive disease were compared with ...
متن کاملRituximab in multiple sclerosis
OBJECTIVE To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). METHODS In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminolog...
متن کاملRituximab versus cyclophosphamide for ANCA-associated vasculitis.
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS We conducted a multicenter, randomized, double-blind, double-dummy, noninferior...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ACTA MEDICA IRANICA
سال: 2020
ISSN: 1735-9694,0044-6025
DOI: 10.18502/acta.v57i8.2413